BioVaxys Technology Corp. is a clinical stage biotechnology company. It engages in developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. The company was founded by James Christopher Passin, Kenneth E. Kovan and David Berd on April 25, 2018 and is headquartered in Etobicoke, Canada.
Sector:
Non Energy Minerals
Industry:
Other Metals Or Minerals
Employees:
N/A
Frequently Asked Questions
What is Market Cap of BioVaxys Technology Corp?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. BioVaxys Technology Corp market cap is $8.75M.
What is the 52-week high for BioVaxys Technology Corp?
52 week high is the highest price of a stock in the past 52 weeks, or one year. BioVaxys Technology Corp 52 week high is $0.08 as of September 05, 2025.
What is the 52-week low for BioVaxys Technology Corp?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. BioVaxys Technology Corp 52 week low is $0.02 as of September 05, 2025.
What is BioVaxys Technology Corp stock price today?
BioVaxys Technology Corp stock price today is $0.025.
What was BioVaxys Technology Corp stock price yesterday?
BioVaxys Technology Corp stock price yesterday was $0.03.
What is the PE ratio of BioVaxys Technology Corp?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. BioVaxys Technology Corp’s P/E ratio is -1.22.
What is the Price-to-Book ratio of BioVaxys Technology Corp?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. BioVaxys Technology Corp P/B ratio is -3.2017.
What is the 50-day moving average of BioVaxys Technology Corp?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. BioVaxys Technology Corp 50-day moving average is $0.0282.
